摘要
目的探究溃疡性直肠炎患者血清中抵抗素(Resistin)的水平及其与C反应蛋白(CRP)、白介素-6(IL-6)的相关性。方法选取2014年9月-2015年9月收治我院经内镜证实的120例溃疡性直肠炎患者血清样本(试验组)和同期研究选取我院体检中心的120例健康体检者血清样本(对照组),并采用酶联免疫吸附(ELISA)检测患者血清中Resistin与CRP、IL-6的水平,分析指标间的相关性。结果与对照组相比,溃疡性直肠炎患者血清中Resistin,CRP,IL-6的水平明显升高(P<0.05),并且随着疾病病情严重程度的增加而升高;溃疡性直肠炎患者血清Resistin与CRP,IL-6呈相关(r=0.425,P=0.021;r=0.631,P=0.013)。结论溃疡性患者血清中Resistin的水平明显升高,并且与血清中CRP,IL-6和疾病病情的严重程度相关。指标的联合检测有利于对溃疡性直肠炎疾病病情的判断。
Objective To investigate the level of resistin in patients with ulcerative proctitis and its correlation with C-reactive protein(CRP)and interleukin-6(IL-6).Methods A total of 120 patients with ulcerative proctitis in our hospital from September 2014 to September 2015 were enrolled in this study.The serum samples of 120 healthy subjects were selected from the experimental group.The serum levels of Resistin,CRP and IL-6 were determined by enzyme-linked immunosorbent assay(ELISA),and the correlation between them was analyzed.Results Compared with the control group,serum levels of Resistin,CRP and IL-6 in patients with ulcerative proctitis were significantly higher(P <0.05)and increased with the severity of ulcerative proctitis;Serum resistin was correlated with CRP and IL-6(r = 0.425,P = 0.021;r = 0.631,P = 0.013).Conclusion Serum levels of Resistin were significantly elevated in patients with ulcerative disease and were associated with serum CRP,IL-6 and the severity of disease progression.The combination of indicators of ulcerative proctitis disease is conducive to the judgment of the disease.
引文
1 Koido S,Ohkusa T,Takakura K,et al.Clinical significance of serum procalcitonin in patients with ulcerative colitis[J].World J Gastroenterol,2013,19(45):8335-8341.
2 Richter JM,Arshi NK,Oster G.Oral 5-aminosalicylate,mesalamine suppository,and mesalamine enema as initial therapy for ulcerative proctitis in clinical practice with quality of care implications[J].Can J Gastroenterol Hepatol,2016,2016:6928710.
3 Actis G C,Rosina F,Pellicano R.A case of appendectomy as main therapeutic intervention for complex co-morbid ulcerative proctitis[J].Int J Colorectal Dis,2015,30(12):1747-1748.
4 赵敏,桑畅野,王振军,等.艾迪莎联合美沙拉嗪栓治疗溃疡性直肠炎的疗效观察[J].海南医学院学报,2016(12):1243-1245.
5 Fukunaga K,Ohda Y,Hida N,et al.Placebo controlled evaluation of Xilei San,a herbal preparation in patients with intractable ulcerative proctitis[J].J Gastroenterol Hepatol,2012,27(12):1808-1815.
6 彭伟,钱秋海,钱卫斌,等.肝脏Resistin与DM非酒精性脂肪肝大鼠糖脂代谢的发生机制及中药干预的作用研究[J].中医药导报,2015(6):29-31.
7 叶鹏.慢性炎症诱导的肝脏脂质沉积小鼠模型中抵抗素表达分泌的变化[D].重庆医科大学,2013.
8 Karmiris K,Koutroubakis IE,Kouroumalis EA.Leptin,adiponectin,resistin,and ghrelin—implications for inflammatory bowel disease[J].Mol Nutr Food Res,2008,52(8):855-866.
9 Konrad A,Lehrke M,Schachinger V,et al.Resistin is an inflammatory marker of inflammatory bowel disease in humans[J].Eur J Gastroenterol Hepatol,2007,19(12):1070-1074.
10 Akram Z,Baharuddin NA,Vaithilingam RD,et al.Effect of nonsurgical periodontal treatment on clinical periodontal variables and salivary resistin levels in obese Asians[J].J Oral Sci,2016.
11 冀元元,李纲,刘志远,等.阿托伐他汀对冠心病炎症因子hs-CRP、TNF-α和IL-6水平的干预作用[J].中国生化药物杂志,2014(07):147-149.
12 Clarke SJ,Smith JT,Gebbie C,et al.A phase I,pharmacokinetic(PK),and preliminary efficacy assessment of ALD518,a humanized anti-IL-6 antibody,in patients with advanced cancer[J].J Clin Oncol,2009,27(15_suppl):3025.
13 Mosli MH,Zou G,Garg SK,et al.C-reactive protein,fecal calprotectin,and stool lactoferrin for detection of endoscopic activity in symptomatic inflammatory bowel disease patients:a systematic review and meta-analysis[J].Am J Gastroenterol,2015,110(6):802-819,820.
14 朱光耀.幼年特发性关节炎临床特征及血清抵抗素的诊断意义[D].上海交通大学,2014.
15 Bouguen G,Roblin X,Bourreille A,et al.Infliximab for refractory ulcerative proctitis[J].Aliment Pharmacol Ther,2010,31(11):1178-1185.
16 李冠华,郭长青,刘青青.复方聚乙二醇电解质散清肠对轻、中度溃疡性结肠炎活动期患者血清中IL-6、CRP水平的影响[J].世界华人消化杂志,2015(35):5711-5714.
17 万国仕,赵振中,钱一龙,等.血清SOCS-3、IL-6、TNF-α在溃疡性结肠炎患者中的变化及其相互关系[J].世界华人消化杂志,2011(32):3370-3373.
18 彭洪,林中超,王程颉,等.IL-4和IL-6在溃疡性直肠炎中的表达及其意义[J].西部医学,2010(12):2271-2273.